VolitionRx (NYSE-A:VNRX) Limited's Cameron Reynolds talks Proactive's Andrew Scott through its results for the year ended December 31, 2021. The company had cash and cash equivalents of around $20.6 million at the year-end, compared with $19.4 million 12 months earlier. Volition is due to receive a $10 million upfront payment as a result of its subsidiary Volition Veterinary signing a licensing and supply agreement with Heska Corporation.
VolitionRx sees potential for 'significant revenue' in its Volition Veterinary business
